<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069316</url>
  </required_header>
  <id_info>
    <org_study_id>030306</org_study_id>
    <secondary_id>03-CC-0306</secondary_id>
    <nct_id>NCT00069316</nct_id>
  </id_info>
  <brief_title>Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease</brief_title>
  <official_title>A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Investigators will assess whether Omr-IgG-am(Trademark), an intravenous immunoglobulin (IVIg)&#xD;
      containing antibodies specific for West Nile virus (WNV), is safe and well-tolerated in&#xD;
      patients with suspected or laboratory diagnosed WNV disease. An initial estimation of&#xD;
      efficacy will also be made.&#xD;
&#xD;
      This Phase I/II study will enroll hospitalized adults with a presumptive diagnosis of West&#xD;
      Nile encephalitis and/or myelitis or those with a positive laboratory test for diagnosis of&#xD;
      WNV infection who are at high risk for progressing to severe neurologic disease based on age&#xD;
      or immunosuppression. Patients will be randomized in blocks of five to receive either&#xD;
      Omr-IgG-am(Trademark), Polygam(Registered Trademark) S/D (IVIG containing minimal anti-WNV&#xD;
      antibodies) or normal saline in a ratio of 3:1:1. Patients and investigators will be blinded&#xD;
      to treatment assignments.&#xD;
&#xD;
      Patients will receive a single intravenous dose of study medication or one of two placebos.&#xD;
      The study participants will receive 0.5 grams/kg of Omr-IgG-am(Trademark) or&#xD;
      Polygam(Registered Trademark) S/D or a comparable volume of normal saline. All patients will&#xD;
      be followed for safety, natural history endpoints, and efficacy. A subset of patients will&#xD;
      have pharmacokinetic measurements of specific anti- WNV antibodies assessed following&#xD;
      treatment.&#xD;
&#xD;
      The primary endpoints are safety and tolerability following Omr-IgG-am(Trademark)&#xD;
      administration.&#xD;
&#xD;
      Secondary endpoints include pharmacokinetics of specific anti-WNV antibodies, mortality in&#xD;
      confirmed WNV positive patients, and the combination of mortality and functional status at&#xD;
      three months in both confirmed WNV-infected patients and all patients by intention to treat.&#xD;
      This combined endpoint will be measured using four standardized measures of cognitive and&#xD;
      functional status: the Barthel Index; the Modified Rankin Scale; the Glasgow Outcome Score;&#xD;
      and the Modified Mini-Mental Status Examination. A comparison of outcomes will be made for&#xD;
      the group receiving Omr-IgG-am(Trademark) versus those receiving either placebo, and between&#xD;
      the two placebo groups. Other secondary endpoints include the proportion of patients in each&#xD;
      group returning to pre-morbid baseline and each subject's improvement at 3 months as compared&#xD;
      to that subject's worst (of any previous) evaluation.&#xD;
&#xD;
      Natural history endpoints will also be assessed. They will include the duration of intensive&#xD;
      care unit (ICU) and hospital stay, development and persistence of WNV-specific IgG and IgM&#xD;
      antibodies, combined functional score and mortality at 3 months between the group with&#xD;
      encephalitis and/or myelitis at baseline versus the group with a positive WNV test only,&#xD;
      outcomes in patients treated late in coma and correlation of outcome with time-to-treatment&#xD;
      following symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will assess whether Omr-IgG-am(Trademark), an intravenous immunoglobulin (IVIg)&#xD;
      containing antibodies specific for West Nile virus (WNV), is safe and well-tolerated in&#xD;
      patients with suspected or laboratory diagnosed WNV disease. An initial estimation of&#xD;
      efficacy will also be made.&#xD;
&#xD;
      This Phase I/II study will enroll hospitalized adults with a presumptive diagnosis of West&#xD;
      Nile encephalitis and/or myelitis or those with a positive laboratory test for diagnosis of&#xD;
      WNV infection who are at high risk for progressing to severe neurologic disease based on age&#xD;
      or immunosuppression. Patients will be randomized in blocks of five to receive either&#xD;
      Omr-IgG-am(Trademark), Polygam(Registered Trademark) S/D (IVIG containing minimal anti-WNV&#xD;
      antibodies) or normal saline in a ratio of 3:1:1. Patients and investigators will be blinded&#xD;
      to treatment assignments.&#xD;
&#xD;
      Patients will receive a single intravenous dose of study medication or one of two placebos.&#xD;
      The study participants will receive 0.5 grams/kg of Omr-IgG-am(Trademark) or&#xD;
      Polygam(Registered Trademark) S/D or a comparable volume of normal saline. All patients will&#xD;
      be followed for safety, natural history endpoints, and efficacy. A subset of patients will&#xD;
      have pharmacokinetic measurements of specific anti- WNV antibodies assessed following&#xD;
      treatment.&#xD;
&#xD;
      The primary endpoints are safety and tolerability following Omr-IgG-am(Trademark)&#xD;
      administration.&#xD;
&#xD;
      Secondary endpoints include pharmacokinetics of specific anti-WNV antibodies, mortality in&#xD;
      confirmed WNV positive patients, and the combination of mortality and functional status at&#xD;
      three months in both confirmed WNV-infected patients and all patients by intention to treat.&#xD;
      This combined endpoint will be measured using four standardized measures of cognitive and&#xD;
      functional status: the Barthel Index; the Modified Rankin Scale; the Glasgow Outcome Score;&#xD;
      and the Modified Mini-Mental Status Examination. A comparison of outcomes will be made for&#xD;
      the group receiving Omr-IgG-am(Trademark) versus those receiving either placebo, and between&#xD;
      the two placebo groups. Other secondary endpoints include the proportion of patients in each&#xD;
      group returning to pre-morbid baseline and each subject's improvement at 3 months as compared&#xD;
      to that subject's worst (of any previous) evaluation.&#xD;
&#xD;
      Natural history endpoints will also be assessed. They will include the duration of intensive&#xD;
      care unit (ICU) and hospital stay, development and persistence of WNV-specific IgG and IgM&#xD;
      antibodies, combined functional score and mortality at 3 months between the group with&#xD;
      encephalitis and/or myelitis at baseline versus the group with a positive WNV test only,&#xD;
      outcomes in patients treated late in coma and correlation of outcome with time-to-treatment&#xD;
      following symptom onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 22, 2003</start_date>
  <completion_date type="Actual">June 27, 2007</completion_date>
  <primary_completion_date type="Actual">June 27, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">2</enrollment>
  <condition>West Nile Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omr-IgG-am</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        In order to participate in this clinical trial, all subjects (or legal representative) must&#xD;
        provide written informed consent. Only patients meeting entry criteria will be enrolled.&#xD;
        Eligible subjects must fall into one of two categories:&#xD;
&#xD;
        A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or&#xD;
        myelitis as defined below:&#xD;
&#xD;
        New neurologic abnormality:&#xD;
&#xD;
        Asymmetric extremity weakness without sensory abnormality; or&#xD;
&#xD;
        Other neurologic abnormality (including altered level of consciousness, dysarthria and&#xD;
        dysphagia) plus fever (subjective or objective) within the previous 4 days&#xD;
&#xD;
        AND&#xD;
&#xD;
        CSF examination within the previous 96 hours showing:&#xD;
&#xD;
        Absence of organism on gram or fungal stain&#xD;
&#xD;
        White blood cell count greater than or equal to 4 per mm(3) corrected for significant red&#xD;
        blood cell contamination.&#xD;
&#xD;
        Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose/plasma glucose&#xD;
        greater than or equal to 0.4)&#xD;
&#xD;
        OR&#xD;
&#xD;
        B. Hospitalized patients without encephalitis and/or myelitis as defined below who meet the&#xD;
        following criteria:&#xD;
&#xD;
        A positive IgM serology or PCR test for WNV in blood or cerebrospinal fluid,&#xD;
&#xD;
        AND&#xD;
&#xD;
        Clinical illness compatible with WNV infection as described by occurrence of greater than&#xD;
        or equal to 3 of the following findings during the preceding less than or equal to 10 days:&#xD;
&#xD;
        Diarrhea, headache, fever greater than 38 degrees Celsius, nausea and/or vomiting, myalgias&#xD;
        and/or arthralgias, nuchal rigidity, macular or papular rash, new neurological abnormality&#xD;
&#xD;
        AND&#xD;
&#xD;
        A risk factor for the development of WNV neurologic disease as defined by:&#xD;
&#xD;
        Age greater than or equal to 40 years, or&#xD;
&#xD;
        Age greater than or equal to 18 years, plus immunosuppression, as defined by any of the&#xD;
        following:&#xD;
&#xD;
        Hematologic malignancy, previous diagnosis of diabetes mellitus, chemotherapy within&#xD;
        previous 4 weeks, stem cell transplant recipient or solid organ transplant recipient,&#xD;
        taking immunosuppressive medications, including prednisone greater than or equal to 7.5&#xD;
        mg/day within the previous 4 weeks, history of human immunodeficiency virus (HIV)&#xD;
        infection, congenital immunodeficiency syndrome (including common variable&#xD;
        immunodeficiency)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Unable to obtain valid informed consent&#xD;
&#xD;
        History of intolerance (including anaphylaxis) to IVIg or related compounds&#xD;
&#xD;
        Known history of IgA deficiency&#xD;
&#xD;
        Known history of hypersensitivity to maltose.&#xD;
&#xD;
        History of (or at time of study entry) hyperviscosity syndrome including but not limited&#xD;
        to:&#xD;
&#xD;
        Waldenstrom's macroglobulinemia&#xD;
&#xD;
        Multiple myeloma&#xD;
&#xD;
        Total white blood cell count greater than 80,000/mm(3)&#xD;
&#xD;
        Hematocrit greater than 55%&#xD;
&#xD;
        Platelet count greater than 700,000/mm(3)&#xD;
&#xD;
        Meets criteria of Class III or IV of the New York Heart Association Classification for&#xD;
        congestive heart failure patients&#xD;
&#xD;
        Serum creatinine greater than 2.5 mg/dL or requires dialysis&#xD;
&#xD;
        Alternate explanation (as determined by the investigator) for clinical findings (such as&#xD;
        structural brain lesion, cerebrovascular accident, or other infectious disease, including&#xD;
        confirmed infections with other flaviviruses)&#xD;
&#xD;
        Pregnant or breastfeeding (negative serum or urine pregnancy test within previous 72 hours&#xD;
        if woman is not postmenopausal or has not been surgically sterilized)&#xD;
&#xD;
        Investigator's opinion that patient would be unable to adhere to protocol requirements&#xD;
&#xD;
        Receipt of ribavirin, interferon alpha, intravenous immunoglobulin or any investigational&#xD;
        drug for treatment of WNV or hepatitis within 15 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7.</citation>
    <PMID>3363593</PMID>
  </reference>
  <reference>
    <citation>Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480-4.</citation>
    <PMID>46957</PMID>
  </reference>
  <reference>
    <citation>McDowell I, Kristjansson B, Hill GB, HÃ©bert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol. 1997 Apr;50(4):377-83.</citation>
    <PMID>9179095</PMID>
  </reference>
  <verification_date>February 18, 2011</verification_date>
  <study_first_submitted>September 22, 2003</study_first_submitted>
  <study_first_submitted_qc>September 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2003</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>NIAID, DMID</name_title>
  </responsible_party>
  <keyword>West Nile Virus</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Virus</keyword>
  <keyword>Mosquito</keyword>
  <keyword>Fever</keyword>
  <keyword>WNV</keyword>
  <keyword>Myelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

